Concentrica LLC

Stoke Therapeutics, Inc., based in Bedford, MA, is pioneering RNA medicine with its proprietary platform, Targeted Augmentation of Nuclear Gene Output (TANGO), aimed at restoring protein expression in diseases caused by gene mutations. The company's focus is primarily on conditions characterized by haploinsufficiencies, including Dravet syndrome and autosomal dominant optic atrophy (ADOA). Stoke's mission is to develop innovative therapies that address the genetic underpinnings of severe diseases, exemplified by their ongoing clinical studies of zorevunersen (STK-001) for Dravet syndrome. Through their commitment to scientific advancement, they aim to improve the lives of patients living with challenges associated with genetic disorders. Generated from the website

From the website:Providing professional, caring, and creative property management solutions essential to building self-reliant communities.